DCF Advisers LLC Takes Position in Corvus Pharmaceuticals, Inc. $CRVS

DCF Advisers LLC bought a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 729,000 shares of the company’s stock, valued at approximately $5,613,000. Corvus Pharmaceuticals accounts for about 1.5% of DCF Advisers LLC’s portfolio, making the stock its 16th biggest position. DCF Advisers LLC owned about 0.87% of Corvus Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of CRVS. Perceptive Advisors LLC bought a new position in Corvus Pharmaceuticals in the 2nd quarter worth $5,754,000. Geode Capital Management LLC raised its holdings in Corvus Pharmaceuticals by 130.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,361,740 shares of the company’s stock worth $5,448,000 after acquiring an additional 771,454 shares during the period. Orbimed Advisors LLC raised its holdings in Corvus Pharmaceuticals by 3.2% in the 2nd quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock worth $28,660,000 after acquiring an additional 221,352 shares during the period. Vanguard Group Inc. raised its holdings in Corvus Pharmaceuticals by 5.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock worth $25,588,000 after acquiring an additional 191,216 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Corvus Pharmaceuticals by 24.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 553,327 shares of the company’s stock worth $4,261,000 after acquiring an additional 107,657 shares during the period. Institutional investors own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on CRVS. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. Oppenheimer reiterated an “outperform” rating and issued a $33.00 target price (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Corvus Pharmaceuticals in a research report on Friday, April 17th. They issued a “buy” rating and a $40.00 price target on the stock. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $33.33.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $11.16 on Thursday. The firm’s 50-day simple moving average is $14.11 and its 200-day simple moving average is $13.64. Corvus Pharmaceuticals, Inc. has a twelve month low of $3.55 and a twelve month high of $26.95. The firm has a market cap of $938.44 million, a P/E ratio of -21.46 and a beta of 0.84.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, equities analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.